Search company, investor...
Search
Vericel company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

vcel.com

Stage

IPO | IPO

Total Raised

$17.6M

Date of IPO

2/4/1997

Market Cap

1.08B

Stock Price

23.64

About Vericel

Vericel, formerly Aastrom Biosciences, develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.

Vericel Headquarters Location

64 Sidney Street

Cambridge, Massachusetts, 02139,

United States

617-588-5555

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Vericel

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vericel is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Vericel Patents

Vericel has filed 5 patents.

The 3 most popular patent topics include:

  • Continuous distributions
  • Discrete distributions
  • Inflammations
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/25/2013

7/3/2018

Tires, Fluid dynamics, Bones of the pelvis, Continuous distributions, Hydrology

Grant

Application Date

11/25/2013

Grant Date

7/3/2018

Title

Related Topics

Tires, Fluid dynamics, Bones of the pelvis, Continuous distributions, Hydrology

Status

Grant

Latest Vericel News

Vericel to Present at the Ladenburg Thalmann Healthcare Conference

Sep 22, 2022

Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Chief Financial Officer Joe Mara will present at the upcoming Ladenburg Thalmann Healthcare Conference. The presentation is scheduled to begin at 2:30 p.m. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com . About Vericel Corporation Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American commercial rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit www.vcel.com . Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2022 Vericel Corporation. All rights reserved. Investor Contacts:

Vericel Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Vericel Rank

  • Where is Vericel's headquarters?

    Vericel's headquarters is located at 64 Sidney Street, Cambridge.

  • What is Vericel's latest funding round?

    Vericel's latest funding round is IPO.

  • How much did Vericel raise?

    Vericel raised a total of $17.6M.

  • Who are the investors of Vericel?

    Investors of Vericel include Tekla Capital Management and Brentwood Associates.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.